CYP19A1 and breast carcinoma: Therefore, we suggest the combination of anastrozole plus oral risedronate in order to prevent aromatase inhibitors-related bone loss, not only in postmenopausal breast cancer women at high-risk of fractures, but also for women at mild-moderate risk.